Pfizer vs Peers
- Market cap
- ₹17,426 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹2,742.62 – ₹5,142.42
Pfizer ranks 1st by market capitalisation among 1 Drug Manufacturers - General companies tracked by ATS. Its largest peers are Pfizer. Its P/E of 22.5 compares with a peer median of 22.5.
Pfizer vs Drug Manufacturers - General peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Pfizer | 3,809.20 | +1.58% | 17,426 | 22.5 | 2.85 | 14.5% | +18.5% |
| Pfizer | 3,809.20 | +1.58% | 17,426 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Pfizer peer comparison — frequently asked questions
Who are Pfizer's competitors?
Pfizer's listed peers in Drug Manufacturers - General include Pfizer, ranked here by market capitalisation.
How does Pfizer's P/E compare with its peers?
Pfizer trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - General peers shown.
Which is the largest company among Pfizer's peers?
By market capitalisation, the largest company in the group is Pfizer at ₹17,426 crore, against ₹17,426 crore for Pfizer.
Same Data For Peers
Trade Pfizer With ATS
Track PFIZER live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.